| Court Determines That University of Pittsburgh and Artecel Have Sole Rights to Adipose-Derived Stem Cell Patent |
|
Cytori and UC lose rights to Adipose-Derived Stem Cells; business agreements and activity under other patents likely affected. Sunnyvale, CA (PRWEB) June 19, 2008 -- Artecel, Inc., announced today that the patent inventorship litigation concerning the foundational, composition-of-matter patent covering stem cells isolated from adipose (fat) tissue has been decided in favor of Artecel’s licensor, the University of Pittsburgh ('Pittsburgh') and against Cytori Therapeutics’ licensor, the University of California ('UC'). Such stem cells are one of the most promising kinds of adult stem cells, easily obtained from patients and able to develop into many different tissue types. The Court determined that only the two scientists at Pittsburgh, Dr. Adam Katz and Dr. Ramon Llull, were inventors, and that Dr. Marc Hedrick and other UC scientists were not inventors. As a result of this decision, UC and Cytori have lost their rights to the patent covering adipose-derived stem cells. Any commercial activities involving these stem cells in the United States -- either under existing business agreements or under other patents relating to the uses or applications of these stem cells -- will likely be affected by this decision. |
